Low-dose Naltrexone: What's New
PCCA Products
•
57m
Join us to discover the latest and greatest in naltrexone compounding with PCCA Clinical Compounding Pharmacist Sebastian Denison, RPh. He'll share updated information you need to know, plus uncover new compounding options to grow your practice.
You'll learn:
New and updated LDN dosing considerations
How LDN is changing the world of dermatology
LDN benefits for cancer patients — and how it can be the starting point for your entry into the oncology practice setting
Up Next in PCCA Products
-
Data and Dosing on Sublingual Deliver...
Download Handouts: https://bit.ly/48Q3kWG
Are you curious about the latest advancements in the sublingual delivery of semaglutide? Join us for an insightful and informative FREE webinar led by PCCA Chief Scientific Officer Gus Bassani, PharmD, PCCA Director of Research & Development Daniel Banov...
-
Solving the Most Common USP 795 Imple...
For pharmacies performing nonsterile compounding, USP 795 is no longer optional. In many states, it’s now mandatory; and where it isn’t yet, it remains the best practice standard for compounding in a way that best protects patient and compounder safety.
Tackle the biggest and easiest-to-miss cha...
-
Semaglutide Sublingually: Clinical Ap...
For pharmacies performing nonsterile compounding, USP 795 is no longer optional. In many states, it’s now mandatory; and where it isn’t yet, it remains the best practice standard for compounding in a way that best protects patient and compounder safety.
Tackle the biggest and easiest-to-miss cha...
